Catabasis Pharmaceuticls Inc. (NASDAQ:CATB) shares traded down 6% on Friday . The stock traded as low as $4.01 and last traded at $5.02, with a volume of 141,453 shares traded. The stock had previously closed at $5.34.

Several research analysts have weighed in on the company. Oppenheimer Holdings Inc. reissued a “buy” rating on shares of Catabasis Pharmaceuticls in a research report on Saturday, May 14th. Cowen and Company reissued a “buy” rating on shares of Catabasis Pharmaceuticls in a research report on Saturday, May 14th. Wedbush reissued an “outperform” rating and issued a $27.00 price objective on shares of Catabasis Pharmaceuticls in a research report on Friday, May 13th. Finally, Zacks Investment Research cut Catabasis Pharmaceuticls from a “buy” rating to a “hold” rating in a research report on Monday, July 18th. One analyst has rated the stock with a hold rating and four have given a buy rating to the stock. The company currently has an average rating of “Buy” and a consensus target price of $19.05.

The stock’s market cap is $77.67 million. The company’s 50-day moving average price is $4.02 and its 200 day moving average price is $4.95.

Catabasis Pharmaceuticls (NASDAQ:CATB) last released its earnings results on Thursday, August 11th. The company reported ($0.61) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.65) by $0.04. Equities analysts forecast that Catabasis Pharmaceuticls Inc. will post ($2.47) earnings per share for the current fiscal year.

Catabasis Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics based on its Safely Metabolized And Rationally Targeted (SMART), a linker drug discovery platform. The SMART linker drug discovery platform enables to engineer product candidates that can modulate multiple targets in a disease.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.